Antihypertensives - New challenges for a maturing market

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2006-09-14

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Datamonitor expects the antihypertensive market to exceed $40bn by 2015 across the seven major markets, with novel treatments and the market-leading ARBs delivering much of this value. However, significant hurdles exist, and pharmaceutical companies need to carefully design marketing campaigns and pricing structures for their products.


Scope

  • Event-driven sales forecasts, for the period 2006-2015, for the US, Japan, France, Germany, Italy, Spain and the UK, plus a global overview
  • Discussion of individual products in four main classes; beta blockers (BBs), CCBs, ACE inhibitors and the ARBs
  • Profiles of the country and market specific issues which will impact future sales in the market including generic erosion and new product launches
  • Commercial impact case studies on R&D innovation, clinical trial data and European healthcare reform


    • Report Highlights
    The growth rate of the antihypertensive market is declining. These changes reflect the challenges faced by pharmaceutical companies over the next decade, as brand erosion and healthcare reforms impact heavily. The slow and declining growth rate does not reflect a stationary market, but the battle between the drugs that make up the market

    Cozaar's patent expiry in the US has the potential to alter the structure of the antihypertensive market dramatically. Threats of generic substitution and money-saving healthcare strategies which have plagued other markets are now approaching the successful ARB class, and will have an impact on the whole antihypertensive market.

    Large pharmaceutical companies that have established themselves in the cardiovascular arena are steering away from development in the antihypertensives market. While still continuing to enjoy large revenues from its cardiovascular arm, the research and development of Novartis shows that it is now investing elsewhere.


    Reasons to Purchase

  • Quantify the future size and scope of the hypertension market and the potential for new products
  • Analyze options to expand commercial potential through pursuit of new indications
  • Formulate successful launch strategies to succeed in a highly competitive market

    • Table of Contents

    Other users found this report page using the following search terms: hypertension antihypertensive blood pressure ace arb market antihypertensive india antihypertensives indian brands arb patent valsartan losartan

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.